Pharma channel feed

Guard­ing against a night­mare sce­nario, FDA ap­proves new drug to counter small­pox out­break

7 years ago

Af­ter long de­lay fol­low­ing pa­tient death, FDA lifts tri­al hold on Ad­vax­is/As­traZeneca com­bo

7 years ago

Sen­ate Dems blast No­var­tis’ ties to Trump at­tor­ney, claim phar­ma gi­ant of­fered mis­lead­ing ex­pla­na­tions in damn­ing re­port

7 years ago

Am­gen, UCB are back pitch­ing once-re­ject­ed os­teo­poro­sis drug ro­mo to the FDA — but big hur­dles lie ahead

7 years ago

FDA lays down the law on gene ther­a­py, of­fer­ing guid­ances on both dis­eases and pro­ce­dures

7 years ago
Cell/Gene Tx

Ra­maswamy’s Der­ma­vant bags GSK’s PhI­II-ready pso­ri­a­sis drug in $330M deal — eye­ing a ma­jor league con­test

7 years ago
R&D

Gen­mab puts down $54M for im­munother­a­py col­lab­o­ra­tion — ready to spend mil­lions more

7 years ago

VC mon­ey booms in Q2, with mega-deals hit­ting record lev­els

7 years ago

Sen­a­tor Wyden prods Trump/Pfiz­er for de­tails, call­ing drug pric­ing stunt 'long on the­atrics, short on re­lief'

7 years ago

Pfiz­er reshuf­fles, split­ting in­to three busi­ness units

7 years ago

No­var­tis punts a late-stage PI3K drug with a wor­ry­ing safe­ty pro­file to one of Chi­na’s up­start biotechs

7 years ago
R&D

Trump claims a big win over Big Phar­ma, forc­ing Pfiz­er to walk back drug price hikes

7 years ago

Chi­na's Tasly Bio­phar­ma turns a de­vel­op­ment part­ner in­to an in­vestor as it preps Hong Kong IPO

7 years ago
China

Caught in a reg­u­la­to­ry lim­bo fol­low­ing FDA hold, EMA spurns Ad­vax­is’ ef­fort to seek con­di­tion­al OK

7 years ago

Trump slams Pfiz­er’s drug price hikes, promis­es to re­tal­i­ate — but how?

7 years ago

Cash-strapped Reg­u­lus braces for dras­tic down­siz­ing while hit­ting the brakes on lead pro­grams

7 years ago
R&D

Ver­tex CEO to UK Prime Min­is­ter: You’re de­valu­ing lives, pass­ing up a great of­fer and threat­en­ing the coun­try’s biotech in­dus­try

7 years ago

Fo­cused on re­build­ing the pipeline, Ax­o­van­t's new crew as­sem­bles an­oth­er pre­clin­i­cal gene ther­a­py deal

7 years ago
R&D

Ap­peas­ing ac­tivist in­vestors, Iron­wood cuts 40 staffers at the start of com­pa­ny split

7 years ago
People
R&D

New Jer­sey's bait worked: Af­ter promise of $40M in in­cen­tives, Te­va is mov­ing its HQ

7 years ago

Trump in­vites phar­ma heads to pri­vate din­ner dur­ing Lon­don vis­it, a trip that's in­spir­ing tens of thou­sands to protest

7 years ago
People

What's BIO and PhRMA do­ing to ad­dress sex­u­al ha­rass­ment? Sen­a­tor Mur­ray wants to know

7 years ago

Af­ter clos­ing the gap on new hires, FDA could face an ex­o­dus of top reg­u­la­tors

7 years ago
R&D

Ac­ne was a bust, but ex­ces­sive sweat­ing scores FDA OK for Der­mi­ra — shares climb

7 years ago
First page Previous page 297298299300301302303 Next page Last page
A service from the Financial Times